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Dear Editor,
I read with interest the article by Yilmaz et al. regarding 
the  value  of  aspartate  aminotransferases  (AST)–to–
platelet  ratio  index  (APRI  score)  for  the  noninvasive 
assessment of liver fibrosis in chronic hepatitis, which 
was  published  in  Hepatitis  Monthly  (1).  The  authors 
evaluated  patients  diagnosed  with  chronic  hepatitis 
C  and  B  and  nonalcoholic  fatty  liver  disease  (NAFLD) 
and assessed their APRI scores to predict the presence 
of fibrosis (Metavir score of at least F1). Most published 
studies have used acoustic radiation force impulse (ARFI) 
elastography results as a predictor of significant fibrosis 
(Metavir score of F ≥ 2) and cirrhosis in chronic hepatitis 
C virus (HCV) infections. A meta-analysis (2) from 2007 
proved that with a cut-off value of 0.5, APRI results had 
81% sensitivity (Se) and 50% specificity (Sp) in predicting 
significant fibrosis (Metavir score of F ≥ 2) and that with 
a cut-off value of 1, the Se and Sp for predicting cirrhosis 
were 76% and 71%, respectively. In a recent meta-analysis 
that included more than 8,700 patients (3), the summary 
of areas under receiver operating characteristic (AUROC) 
values of APRI for the diagnosis of significant fibrosis, 
severe fibrosis, and cirrhosis were 0.77, 0.80, and 0.83, 
respectively. For significant fibrosis, the Se and Sp of an 
APRI threshold of 0.7 were 77% and 72%, respectively, and 
the corresponding values obtained with a threshold of 
1.0 for severe fibrosis were 61% and 64%, respectively. For 
cirrhosis, the Se and Sp of an APRI threshold of 1.0 were 
76% and 72%, respectively (3). In the study by Yilmaz et al. 
(1), for an optimal cut-off point of > 0.44, the APRI score 
was a poor predictor of fibrosis (F ≥ 1), with an Se and Sp 
of 72.7% and 62.4% (AUROC = 0.582), which was expected 
since  all  noninvasive  tests  show  poor  performance  in 
differentiation of the early stages of fibrosis.
Regarding hepatitis B virus (HBV) infection, a recently 
published study from China (4) showed that age could 
be a factor influencing the ARFI threshold that separates 
patients without fibrosis from those with a Metavir score 
of at least F1, the cut-off points being 0.11 for patients 
aged  <  35  years  and  0.18  for  those  >35  years.  A  study 
from France showed that the APRI values (0.28 vs. 0.43; 
P < 0.0001) were significantly lower in inactive hepatitis 
B surface antigen (HBsAg) carriers than in patients with 
chronic  HBV  infection  (5).  Although  in  the  study  by 
Yilmaz et al. (1) in patients with chronic HBV infection, 
the APRI score could not help differentiate subjects with Hepat Mon. 2011;11(7):560-561
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a Metavir score of F0 from those with a Metavir score of at 
least F1, there are other published data showing that APRI 
can be a valuable predictor of significant fibrosis (F ≥ 2) 
and cirrhosis, similar to its predictive value in patients 
with chronic HCV infection (6), with AUROC values of 
0.81  (0.74–0.87)  and  0.83  (0.77–0.90),  respectively.  Few 
studies have been published regarding the value of APRI 
in NAFLD, and these studies showed that the APRI values 
tended  to  increase  with  the  severity  of  fibrosis  (7,  8). 
Further studies are required to validate these findings. 
Overall, considering the wide availability and low cost 
of performing APRI, we think that it can be a useful tool 
for the evaluation of fibrosis in patients with chronic 
hepatitis, possibly in association with other tests, or for 
repetitive evaluation to assess the progression of fibrosis 
(9).
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